BRCA2 and breast carcinoma: For BRCA2 heterozygotes, the ER-positive PRS313 effect size for the association with contralateral breast cancer risk was nonsignificantly smaller among heterozygotes of a pathogenic variant that lead to a stable mutant protein, although statistical power to detect these associations was low and the confidence intervals overlap with the overall estimate (Table 2).